Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Guillot Morales
Observed names:
M.M. Guillot Morales,
Monica Guillot,
Mónica Guillot,
Mónica Guillot Morales,
Mónica Guillot-Morales
Institutions:
Health Research Institute of the Balearic Islands,
Hospital Universitario Son Espases
Observed institutions:
Health Research Institute of the Balearic Islands,
Hospital Universitario Son Espases,
Sociedad Española de Oncología Médica,
Universitat de les Illes Balears
ORCID:
0000-0001-7509-146X
Observed ORCID:
0000-0001-7509-146X
OpenAlex ID:
A5043673524
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025
·
Caiming Xu
, Alessandro Mannucci
, et al.
·
Clinical Cancer Research
·
24
Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology
2024
·
Mónica Guillot Morales
, Laura Visa
, et al.
·
Clinical & Translational Oncology
·
15
PDF
1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
2022
·
M.R. Garcia Campelo
, M. Domine Gomez
, et al.
·
Annals of Oncology
·
11
Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions
2025
·
Regina Gironés Sarrió
, Javier David Benítez Fuentes
, et al.
·
Clinical & Translational Oncology
·
6
PDF
1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
2023
·
M.R. García-Campelo
, M. Dómine
, et al.
·
Annals of Oncology
·
4
Challenges in DPYD Test Implementation in Patients Treated with Fluoropyrimidines are DPYD Genotype Arriving on Time? [Letter]
2023
·
Marta López López-Cepero
, Antonia Obrador de Hevia
, et al.
·
Pharmacogenomics and Personalized Medicine
·
3
PDF
P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
2023
·
R. García-Campelo
, M. Dómine Gómez
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
Validation and pilot feasibility study of a novel screener to assess diet, lifestyle and mental health in people living with and beyond cancer: Study protocols
2025
·
Alice Chaplin
, Janna Wordsworth
, et al.
·
PLoS ONE
·
2
PDF
Inflammatory circulating biomarkers in non-small cell lung cancer: profile description and survival assessment
2026
·
L. ValiÑa Amado
, E. Martínez Font
, et al.
·
Clinica Chimica Acta
Impact of a lifestyle intervention on the quality of life of people living with and beyond cancer – a feasibility study
2026
·
Janna Wordsworth
, Lara Prohens
, et al.
·
Health and Quality of Life Outcomes
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
2025
·
Mercedes Salgado
, Juan de la Camara-Gómez
, et al.
·
BMC Cancer
PDF
814P Lactate dehydrogenase as a predictive biomarker to anti-epidermal growth factor receptor therapy, in RAS/BRAF wild-type left sided, metastatic colorectal cancer: A GEMCAD study
2025
·
M.S. Rojas Piedra
, S. Madurga
, et al.
·
Annals of Oncology
Identifying the key components of a diet and lifestyle screener for people living with and beyond cancer: an e-Delphi study
2025
·
Alice Chaplin
, Lara Prohens
, et al.
·
BMJ Open
PDF
Data from An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025
·
Caiming Xu
, Alessandro Mannucci
, et al.
Supplementary Data 2 from An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025
·
Caiming Xu
, Alessandro Mannucci
, et al.
Supplementary Data 1 from An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study
2025
·
Caiming Xu
, Alessandro Mannucci
, et al.
P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study
2024
·
R. García-Campelo
, M. Dómine Gómez
, et al.
·
Journal of Thoracic Oncology
PDF
EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
2024
·
J. de Castro
, M. Cobo Dols
, et al.
·
Journal of Thoracic Oncology
PDF
1792P Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
2024
·
M. Cobo Dols
, M. Dómine Gómez
, et al.
·
Annals of Oncology
PDF
P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC
2023
·
M. Dómine Gómez
, M. Cobo Dols
, et al.
·
Journal of Thoracic Oncology
PDF
PB0980 TINzaparin PROphylaxis in Patients with Metastatic COLorectal Cancer (PROTINCOL)
2023
·
A. Muñoz Martín
, J. de la Cámara Gómez
, et al.
·
Research and Practice in Thrombosis and Haemostasis
Show more works
View as search
Works count:
22
Citation count:
68
H-index:
4
I10-index:
3
Year
Topic
Type